The use of PCV chemotherapy in oligodendrogliomas

Michael W. Ruff, Jan C. Buckner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Oligodendrogliomas are now defined by the presence of whole-arm co-deletion in chromosomal arms 1p and 19q. The treatment paradigm for oligodendroglioma has shifted, owing to new diagnostic criteria and phase III clinical trial evidence. The treatment with radiation therapy plus chemotherapy with procarbazine, lomustine, and vincristine (PCV) results in prolongation of both progression-free and OS compared to treatment with radiation alone. Clinical trials, including RTOG 9402, EORTC 26951, and RTOG 9802, in contrast to NOA-04 and EORTC 22033, have conclusively demonstrated that chemoradiation is superior to either radiation therapy alone or chemotherapy alone for patients with oligodendroglioma. Regardless of grade, PCV chemotherapy, in addition to radiation, has a clear benefit in patients with oligodendroglioma and IDH mutated astrocytoma. Temozolomide may be less effective in the treatment of oligodendroglioma, but clearly has a benefit in astrocytoma.

Original languageEnglish (US)
Title of host publicationOligodendroglioma
Subtitle of host publicationClinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment
PublisherElsevier
Pages331-339
Number of pages9
ISBN (Electronic)9780128131589
ISBN (Print)9780128131596
DOIs
StatePublished - Jan 1 2019

Keywords

  • 1p/19q
  • Idh
  • Oligodendroglioma
  • Pcv
  • Temozolomide

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'The use of PCV chemotherapy in oligodendrogliomas'. Together they form a unique fingerprint.

  • Cite this

    Ruff, M. W., & Buckner, J. C. (2019). The use of PCV chemotherapy in oligodendrogliomas. In Oligodendroglioma: Clinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment (pp. 331-339). Elsevier. https://doi.org/10.1016/B978-0-12-813158-9.00028-1